| Drug General Information |
| Drug ID |
D0A8IE
|
| Former ID |
DNCL003116
|
| Drug Name |
AM-831
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Discontinued in Phase 1 |
[1]
|
|---|
| Company |
ACADIA Pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C7H14ClNO3
|
| Canonical SMILES |
COC(=O)C1(CCOCC1)N.Cl
|
| InChI |
1S/C7H13NO3.ClH/c1-10-6(9)7(8)2-4-11-5-3-7;/h2-5,8H2,1H3;1H
|
| InChIKey |
VNPBPEQYIQVYDP-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
83100158, 87166407, 123219523, 125504745, 143460775, 160659184, 162087997, 164199653, 170497886, 185982257, 202822044, 224177163, 227992766, 249735252, 250183937, 252669800
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 2A receptor |
Target Info |
Agonist |
[2]
|
|---|
| D(2) dopamine receptor |
Target Info |
Agonist |
[2]
|
| Acetylcholine receptor |
Target Info |
Agonist |
[2]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channelshsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (q) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390648:Muscarinic acetylcholine receptors
|
|
Acetylcholine regulates insulin secretion
|
|
Highly sodium permeable acetylcholine nicotinic receptors
|
|
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Nicotine Activity on Dopaminergic NeuronsWP2754:Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016551) |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Avarx. |
|---|
